BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38251561)

  • 21. Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort.
    Doubelt I; Pulenzas N; Carette S; Pagnoux C;
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):171-175. PubMed ID: 32167871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis.
    Belfeki N; Abroug S; Ghriss N; Chouchane I; Hamrouni S; Strazzulla A; Zayet S
    Clin Exp Rheumatol; 2021 Oct; 40(4):834-837. PubMed ID: 35522541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.
    Teixeira V; Mohammad AJ; Jones RB; Smith R; Jayne D
    RMD Open; 2019; 5(1):e000905. PubMed ID: 31245051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term Safety and Efficacy of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis Complicated with Severe Neuropathy.
    Koga Y; Yoshimi S; Harada T; Suzuki S; Ohtsuka T; Dobashi K; Hisada T
    Intern Med; 2023 May; 62(10):1553-1556. PubMed ID: 36171130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benralizumab in eosinophilic granulomatosis with polyangiitis complicated by Staphylococcus aureus sepsis.
    Kolios AGA; Lutterotti A; Kulcsar Z; Renner T; Rudiger A; Nilsson J
    Clin Immunol; 2021 Jan; 222():108574. PubMed ID: 32805452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis.
    Ueno M; Miyagawa I; Nakano K; Iwata S; Hanami K; Fukuyo S; Kubo S; Miyazaki Y; Kawabe A; Yoshinari H; Nakayamada S; Tanaka Y
    Arthritis Res Ther; 2021 Mar; 23(1):86. PubMed ID: 33726827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
    Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
    J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
    Mohammad AJ; Hot A; Arndt F; Moosig F; Guerry MJ; Amudala N; Smith R; Sivasothy P; Guillevin L; Merkel PA; Jayne DR
    Ann Rheum Dis; 2016 Feb; 75(2):396-401. PubMed ID: 25467294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.
    Detoraki A; Tremante E; Poto R; Morelli E; Quaremba G; Granata F; Romano A; Mormile I; Rossi FW; de Paulis A; Spadaro G
    Respir Res; 2021 Jun; 22(1):185. PubMed ID: 34162391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
    Yamane T; Hashiramoto A
    Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
    Thiel J; Hässler F; Salzer U; Voll RE; Venhoff N
    Arthritis Res Ther; 2013 Sep; 15(5):R133. PubMed ID: 24286362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis.
    Mümmler C; Mertsch P; Barnikel M; Haubner F; Schönermarck U; Grabmaier U; Schulze-Koops H; Behr J; Kneidinger N; Milger K
    J Asthma Allergy; 2024; 17():557-572. PubMed ID: 38860030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.
    Quan MV; Frankel SK; Maleki-Fischbach M; Tan LD
    BMC Pulm Med; 2018 Nov; 18(1):181. PubMed ID: 30497438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monocentric study of IL-5 monoclonal antibody induction therapy for eosinophilic granulomatosis with polyangiitis.
    Wang CR; Tsai HW; Shieh CC
    J Formos Med Assoc; 2024 Jul; 123(7):802-810. PubMed ID: 38199911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the pharmacotherapeutic management of eosinophilic granulomatosis with polyangiitis.
    Pagnoux C; Berti A
    Expert Opin Pharmacother; 2023; 24(11):1269-1281. PubMed ID: 37204027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and long-term outcome of patients with gastrointestinal involvement in eosinophilic granulomatosis with polyangiitis.
    Li R; Chen Y; Zhang S; Peng L; Zhou J; Fei Y; Zhang W; Zhao Y; Zeng X
    Front Immunol; 2022; 13():1099722. PubMed ID: 36713417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study.
    Ueno M; Miyagawa I; Aritomi T; Kimura K; Iwata S; Hanami K; Fukuyo S; Kubo S; Miyazaki Y; Nakayamada S; Tanaka Y
    Arthritis Res Ther; 2022 Jun; 24(1):159. PubMed ID: 35768825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis.
    Manka LA; Guntur VP; Denson JL; Dunn RM; Dollin YT; Strand MJ; Wechsler ME
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):696-701.e1. PubMed ID: 33548468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis.
    Tsurikisawa N; Oshikata C; Watanabe M; Tsuburai T; Kaneko T; Saito H
    Clin Exp Allergy; 2018 Oct; 48(10):1305-1316. PubMed ID: 29908086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benralizumab in the management of rare primary eosinophilic lung diseases.
    Griscti Soler D; Bennici A; Brunetto S; Gangemi S; Ricciardi L
    Allergy Asthma Proc; 2022 Nov; 43(6):494-500. PubMed ID: 36335418
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.